Cardiology in Wisconsin

Imaging Biometrics develops quantitative medical imaging analysis software focused on neuro-oncology and brain tumor characterization. The company specializes in advanced post-processing algorithms and plugins that enhance MRI interpretation, particularly for contrast-enhanced imaging and perfusion analysis. Core product offerings include FTB Maps (for tumor characterization), IB Nimble (clinical workflow integration), IB Neuro (neuroimaging analysis with Delta T1 and rCBV mapping), IB Diffusion, IB DCE (dynamic contrast-enhanced imaging), IB Delta Suite, IB Rad Tech, and IB StoneChecker. The software leverages proprietary quantitative technology including Delta T1 (standardized T1 subtraction) and relative cerebral blood volume (rCBV) mapping to improve accuracy in assessing residual enhancing tumors, differentiating sellar lesions, and guiding surgical and therapeutic management. Products are designed for PACS compatibility and clinical implementation in hospital radiology departments and neuro-oncology centers. The company serves academic medical centers, community hospitals, and research institutions internationally, with particular strength in European and North American markets. Imaging Biometrics emphasizes clinical validation through peer-reviewed publications and collaborations with academic neuroradiologists and neuro-oncologists. Software is available as Mac plugins with free trial and demonstration options. The company maintains direct clinical support and works with institutional research teams on imaging-guided surgical planning and radiation therapy applications.

Voximetry provides advanced dosimetry software and clinical services for radiopharmaceutical therapy (RPT), enabling personalized cancer treatment guidance. The company addresses significant variability in patient response to RPT (up to 10-fold differences) through GPU-accelerated dose assessment technology and expert dosimetry services. Voximetry offers three primary service lines: (1) Torch®, a proprietary software platform for analyzing nuclear medicine scans to calculate patient-specific pharmacokinetics and radiation dose estimates to tumors and critical organs; (2) Advanced Dosimetry Services for clinical use, delivered as a managed service to minimize capital expenditure and IT complexity for healthcare providers; and (3) Dosimetry Services for RPT clinical trials, supporting researchers and contract research organizations in meeting trial dosimetry requirements without in-house deployment. The company targets oncology departments, nuclear medicine clinics, academic medical centers, and pharmaceutical companies conducting RPT development. Voximetry operates as a software-as-a-service and laboratory service provider, positioning itself to routinize sophisticated patient-specific dosimetry in clinical practice and clinical research. The organization has partnered with major CROs (e.g., Medpace) and received recognition as a finalist for the 2025 Siemens Healthineers Startup Award.

Nexstim Plc manufactures navigated transcranial magnetic stimulation (nTMS) and repetitive TMS (rTMS) systems for clinical diagnosis, surgical planning, and therapeutic applications. The company's primary products are the SmartFocus® nTMS and NBS System platforms, which use 3D imaging and image-guided navigation to precisely target and quantify the electric field dose delivered to the brain. Clinical applications include motor and language mapping for presurgical planning in neurosurgery and epilepsy, treatment of major depressive disorder (FDA cleared), obsessive-compulsive disorder (OCD; FDA cleared as of 2026), and post-operative rehabilitation for spinal cord injury and complex regional pain syndrome (CRPS). The systems are used in academic medical centers, children's hospitals, and specialized neurosurgery and psychiatry clinics worldwide. Nexstim holds FDA 510(k) clearances and CE/MDR certification for multiple therapeutic indications. The company serves neurosurgeons, neuroradiologists, epileptologists, psychiatrists, and rehabilitation specialists. The technology integrates real-time neurophysiological feedback (motor evoked potentials, MEP recording) with anatomical imaging to guide clinical decision-making and optimize patient outcomes.

Macan Genesis Manufacturing LLC is a specialized manufacturer of electrosurgical units with over 60 years of industry experience. The company focuses exclusively on radio frequency (RF) and high-frequency technology for surgical applications, serving both dental and medical markets. Macan designs and manufactures precision electrosurgical units featuring spark-free RF technology, bipolar coagulation handpieces, and surgical tissue management solutions. The company emphasizes quality, safety compliance, and engineering excellence to meet the exacting demands of healthcare professionals. Products are built to deliver reliability and effectiveness in precision tissue cutting and coagulation procedures.

Accuray Incorporated is a global leader in radiation oncology and radiosurgery systems. The company manufactures advanced treatment platforms designed to deliver precise radiation therapy across a full spectrum of patient needs, with 479+ systems installed in 33+ countries. Accuray's primary product lines include the CyberKnife® S7™, a robotic stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) system featuring AI-driven real-time motion synchronization for tumor treatment anywhere in the body, and the Radixact® system, which combines integrated 3D kVCT and megavoltage CT (MVCT) imaging for image-guided intensity-modulated radiation therapy (IG-IMRT) and 3D conformal radiation therapy (3DCRT). Both systems are designed to improve treatment precision, reduce workflow complexity, and enhance patient outcomes. Accuray serves oncology centers, hospitals, and specialized radiotherapy facilities globally. The company emphasizes quality of care, efficiency of workflow, and clinician confidence through continuous innovation. Over 31% of system components are sourced from U.S. suppliers. Accuray supports its installed base through comprehensive training programs, the AEx® peer community platform for user education and experience-sharing, and dedicated service and reimbursement support. The company operates in the high-stakes cancer treatment market, addressing complex cases including prostate, lung, brain, and other tumor types.

Leo Cancer Care Incorporated develops and manufactures innovative radiation therapy systems designed to deliver cancer treatment in an upright patient position, challenging traditional supine radiotherapy conventions. The company specializes in two primary solution platforms: Marie, an award-winning upright particle therapy system named after Marie Curie, which integrates comprehensive imaging and treatment delivery for particle-based cancer treatment; and Grace, an emerging upright photon therapy solution combining an ultra-fast multileaf collimator (MLC), fan-beam CT scanner, and proprietary upright patient positioning system (currently pre-commercial). The company's core innovation centers on reintroducing upright positioning—reflecting natural human posture—to improve patient comfort, anatomical consistency, and clinical outcomes. Leo Cancer Care operates in the global oncology equipment market, serving cancer treatment centers and research institutions. The company has demonstrated clinical adoption through installations at leading cancer centers and collaborations with major medtech partners, including Fosun MedTech for particle therapy deployment in Asia. Additionally, Leo Cancer Care develops supportive care solutions, partnering with organizations like Xploro to create patient engagement tools such as Statue Quest, a game designed to support pediatric and adolescent patients undergoing radiation therapy. The company maintains a commitment to evidence-based clinical validation, as evidenced by recent landmark whitepaper publication on anatomical variations between supine and upright treatment positions.